Publication

IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen

Lee, S. M.
; 
Schulz, C.
; 
Prabhash, K.
; 
Han, B.
; 
Szczesna, A.
; 
Cortinovis, D. L.
; 
Rittmeyer, A.
; 
Baz, D. V.
; ; 
Anh, L. T.
... show 10 more
Citations
Altmetric:
Abstract
Authors
Lee, S. M.
Schulz, C.
Prabhash, K.
Han, B.
Szczesna, A.
Cortinovis, D. L.
Rittmeyer, A.
Baz, D. V.
Califano, Raffaele
Anh, L. T.
Liu, G.
Cappuzzo, F.
Contreras, J. G. R.
Reck, M.
Hu, Y.
Morris, S.
Hoeglander, E. K.
Connors, M.
Vollan, H. K. M.
Peters, S.
Affiliation
Dept Of Oncology, University College London Hospitals NHS Foundation Trust, UCL Cancer Institute and CRUK Lung Cancer Centre of Excellence, NW1 2PG - London/GB
Description
Date
2022
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Lee SM, Schulz C, Prabhash K, Han B, Szczesna A, Cortinovis DL, et al. IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen. Annals of Oncology. 2022 Sep;33(7):S1418-S9. PubMed PMID: WOS:000866211602462.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/625985
Embedded videos